To investigate the relevance of concomitant BRAF and KIT/PDGFRA mutations in primary and secondary resistance to Imatinib, we conducted a molecular study of the hot spots of KIT, PDGFRA and BRAF. Only one case out of the 407 analyzed GIST carried the BRAF V600E mutation. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.